In addition to MED12, TERT-promoter, RARA and TP53 variants are frequent in malignant PTs, and one study showed that MED12 mutations were associated with improved disease-free survival rates and a reduced likelihood of recurrence, and TP53 mutations were usually associated with tumor grade progression[23, 25, 26]. This evidence concerns the gene TERT and neoplasm.